Literature DB >> 8612317

Carboplatin and vinorelbine in advanced non-small-cell lung cancer.

P Pronzato1, E Ghio, P L Losardo, M Landucci, F Vaira, A Vigani.   

Abstract

A total of 32 patients with advanced non-small-cell lung cancer were treated with carboplatin (350 mg/m2, day 1) and vinorelbine (days 1 and 8) every 28 days. A response rate of 28% (95% confidence limits 12.5 - 43.7%) was observed. The activity of this combination was demonstrated in an outpatient setting with acceptable toxicity.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8612317     DOI： 10.1007/s002800050436

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  5 in total

Review 1.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Effect of vinorelbine monotherapy in taxane-treated patients with advanced non-small-cell lung cancer.

Authors:  Junya Miyata; Takahiro Sano; Hiroyasu Bando
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 3.  Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management.

Authors:  Richard J Gralla; Ulrich Gatzemeier; Vittorio Gebbia; Rudolf Huber; Mary O'Brien; Christian Puozzo
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.

Authors:  C von Plessen; B Bergman; O Andresen; R M Bremnes; S Sundstrom; M Gilleryd; R Stephens; J Vilsvik; U Aasebo; S Sorenson
Journal:  Br J Cancer       Date:  2006-10-03       Impact factor: 7.640

5.  Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).

Authors:  E Baldini; C Tibaldi; A Ardizzoni; F Salvati; A Antilli; L Portalone; S Barbera; F Romano; F De Marinis; M R Migliorino; M A Noseda; U Borghini; M Crippa; G Ferrara; M Raimondi; M Fioretti; M Bandera; M C Pennucci; G Galeasso; G C Cacciani; G Lepidini; G Sunseri; C Lanfranco; M Rinaldi; R Rosso
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.